Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis.
cyclosporin
trough levels
ulcerative colitis
ustekinumab
Journal
Therapeutic advances in gastroenterology
ISSN: 1756-283X
Titre abrégé: Therap Adv Gastroenterol
Pays: England
ID NLM: 101478893
Informations de publication
Date de publication:
2020
2020
Historique:
received:
19
06
2020
accepted:
06
08
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
27
10
2020
Statut:
epublish
Résumé
The therapeutic management of patients with severe steroid-refractory ulcerative colitis still represents a critical clinical challenge. In this setting, cyclosporin is an effective and rapidly acting induction treatment that is applied in combination with maintenance therapeutic agents like thiopurines or vedolizumab. Here, we present the case of a 33-year-old ulcerative colitis patient with severe steroid-refractory ulcerative colitis who refused surgical intervention and previously demonstrated no long-term benefit to anti-TNF antibody, vedolizumab, cyclosporin, thiopurines or tofacitinib treatment. Intravenous cyclosporin therapy was re-initiated in the patient and, after signs of clinical response, therapy with ustekinumab was additionally applied. After 11 weeks of well tolerated cyclosporin and ustekinumab combination therapy, cyclosporin was discontinued upon clinical and endoscopic remission. Subsequently, ustekinumab treatment has been effective in maintaining remission during the follow-up period of 195 days.
Identifiants
pubmed: 33101457
doi: 10.1177/1756284820954112
pii: 10.1177_1756284820954112
pmc: PMC7550934
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1756284820954112Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: R.A. and M.F.N. received honoraria for lectures and consulting fees from Janssen-Cilag
Références
Gastroenterology. 2005 Jun;128(7):1805-11
pubmed: 15940615
Clin Gastroenterol Hepatol. 2019 Feb;17(3):494-501
pubmed: 30213584
Gastroenterology. 2003 Oct;125(4):1025-31
pubmed: 14517785
Clin Gastroenterol Hepatol. 2019 Apr;17(5):988-990.e1
pubmed: 30458248
Lancet. 2012 Dec 1;380(9857):1909-15
pubmed: 23063316
Aliment Pharmacol Ther. 2018 Jul;48(1):65-77
pubmed: 29797519
Clin Gastroenterol Hepatol. 2020 Sep;18(10):2244-2255.e9
pubmed: 31816446
Gut. 2018 Feb;67(2):237-243
pubmed: 28053054
Am J Gastroenterol. 2016 Apr;111(4):477-91
pubmed: 26856754
Am J Gastroenterol. 1999 Jun;94(6):1587-92
pubmed: 10364029
BMC Gastroenterol. 2007 Mar 27;7:13
pubmed: 17389040
World J Gastroenterol. 2015 Jan 7;21(1):254-61
pubmed: 25574099
Lancet Gastroenterol Hepatol. 2016 Sep;1(1):15-24
pubmed: 27595142
Ann Pharmacother. 2006 Jan;40(1):96-101
pubmed: 16368919
Aliment Pharmacol Ther. 2020 Jun;51(11):1039-1046
pubmed: 32291786
N Engl J Med. 1994 Jun 30;330(26):1841-5
pubmed: 8196726
Aliment Pharmacol Ther. 2020 Mar;51(6):637-643
pubmed: 31875986
J Drugs Dermatol. 2013 Oct;12(10):1098-102
pubmed: 24085044
J Crohns Colitis. 2019 Sep 19;13(9):1105-1110
pubmed: 30726894
Gastroenterology. 2001 May;120(6):1323-9
pubmed: 11313301
J Crohns Colitis. 2018 Apr 27;12(5):629
pubmed: 29272353
J Crohns Colitis. 2020 Jul 30;14(7):1026-1028
pubmed: 32020189
N Engl J Med. 2019 Sep 26;381(13):1201-1214
pubmed: 31553833
Clin Gastroenterol Hepatol. 2019 Feb;17(3):486-493
pubmed: 29751166